DE69322957D1 - L - Deprenyl zur Behandlung von makulärer Degeneration - Google Patents

L - Deprenyl zur Behandlung von makulärer Degeneration

Info

Publication number
DE69322957D1
DE69322957D1 DE69322957T DE69322957T DE69322957D1 DE 69322957 D1 DE69322957 D1 DE 69322957D1 DE 69322957 T DE69322957 T DE 69322957T DE 69322957 T DE69322957 T DE 69322957T DE 69322957 D1 DE69322957 D1 DE 69322957D1
Authority
DE
Germany
Prior art keywords
deprenyl
macular degeneration
treatment
disease
ameliorate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69322957T
Other languages
English (en)
Other versions
DE69322957T2 (de
Inventor
Hastings Barbara Fries
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somerset Pharmaceuticals Inc
Original Assignee
Somerset Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somerset Pharmaceuticals Inc filed Critical Somerset Pharmaceuticals Inc
Publication of DE69322957D1 publication Critical patent/DE69322957D1/de
Application granted granted Critical
Publication of DE69322957T2 publication Critical patent/DE69322957T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
DE69322957T 1992-04-23 1993-04-23 L - Deprenyl zur Behandlung von makulärer Degeneration Expired - Fee Related DE69322957T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/872,839 US5242950A (en) 1992-04-23 1992-04-23 Treatment of macular degeneration
PCT/US1993/003862 WO1993021894A2 (en) 1992-04-23 1993-04-23 Treatment of macular degeneration

Publications (2)

Publication Number Publication Date
DE69322957D1 true DE69322957D1 (de) 1999-02-18
DE69322957T2 DE69322957T2 (de) 1999-07-01

Family

ID=25360402

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69322957T Expired - Fee Related DE69322957T2 (de) 1992-04-23 1993-04-23 L - Deprenyl zur Behandlung von makulärer Degeneration

Country Status (14)

Country Link
US (1) US5242950A (de)
EP (1) EP0637238B1 (de)
JP (1) JP2669721B2 (de)
AT (1) ATE175348T1 (de)
AU (1) AU679679B2 (de)
BR (1) BR9306283A (de)
CA (1) CA2133998C (de)
DE (1) DE69322957T2 (de)
DK (1) DK0637238T3 (de)
ES (1) ES2127819T3 (de)
GR (1) GR3029670T3 (de)
HU (1) HU224917B1 (de)
NO (1) NO944018L (de)
WO (1) WO1993021894A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US5783606A (en) * 1995-02-10 1998-07-21 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
AU723047B2 (en) 1995-02-10 2000-08-17 University Of Toronto Innovations Foundation, The Deprenyl compounds for treatment of glaucoma
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
JPH11506744A (ja) 1995-06-07 1999-06-15 ノウブン ファーマシューティカルズ インク． 室温で液体である低分子量薬を含む経皮組成物
US5827652A (en) 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
AU707646B2 (en) * 1995-11-06 1999-07-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
DE69902520T2 (de) 1998-03-16 2003-04-10 Somerset Pharmaceuticals Inc Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
US7691406B2 (en) * 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
EP1441708B1 (de) * 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
EP1565185A4 (de) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation Neuroprotektive eisenchelatoren und pharmazeutische zusammensetzungen damit
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20040180090A1 (en) * 2003-03-12 2004-09-16 Demarco Peter Treatment of macular degeneration
EP1622450A4 (de) * 2003-04-25 2009-11-18 Endo Pharmaceuticals Solutions Verfahren zur förderung des durchschlafens durch verabreichung von trospiumchlorid
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
EP1686973A4 (de) 2003-11-25 2009-03-25 Technion Res & Dev Foundation Zusammensetzungen und verfahren zur behandlung von kardiovaskulären erkrankungen und krankheiten
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
US20090208556A1 (en) * 2004-10-29 2009-08-20 Regents Of The University Of California, The Porous photonic crystals for drug delivery to the eye
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CA2658246A1 (en) * 2006-07-28 2008-01-31 Alcon Research Ltd. Monoamine oxidase inhibitors useful for treating disorders of the outer retina
KR20170084358A (ko) * 2007-07-10 2017-07-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
BR112012019374B1 (pt) 2010-02-03 2022-01-11 Pharma Two B Ltd Composição farmacêutica oral e uso de um agente ativo para a preparação de uma composição farmacêutica oral para o tratamento de doenças neurodegenerativas
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
AU2016291224B2 (en) 2015-07-09 2021-12-23 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US4868218A (en) * 1987-08-18 1989-09-19 Buyske Donald A Method of treating depression
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same

Also Published As

Publication number Publication date
EP0637238A1 (de) 1995-02-08
WO1993021894A3 (en) 1994-01-20
EP0637238B1 (de) 1999-01-07
ES2127819T3 (es) 1999-05-01
WO1993021894A2 (en) 1993-11-11
NO944018D0 (no) 1994-10-21
JP2669721B2 (ja) 1997-10-29
CA2133998C (en) 2006-03-21
CA2133998A1 (en) 1993-11-11
JPH07505906A (ja) 1995-06-29
US5242950A (en) 1993-09-07
ATE175348T1 (de) 1999-01-15
HU9403052D0 (en) 1994-12-28
NO944018L (no) 1994-10-21
AU4033993A (en) 1993-11-29
BR9306283A (pt) 1998-06-30
DK0637238T3 (da) 1999-08-30
HUT72295A (en) 1996-04-29
AU679679B2 (en) 1997-07-10
GR3029670T3 (en) 1999-06-30
HU224917B1 (en) 2006-04-28
DE69322957T2 (de) 1999-07-01

Similar Documents

Publication Publication Date Title
ATE175348T1 (de) L - deprenyl zur behandlung von makulärer degeneration
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ATE71629T1 (de) Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels.
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE179888T1 (de) Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69833727D1 (de) Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
DE69800906T2 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
RU93046326A (ru) Способ лечения медикаментозных эзофаго-гингиво-стоматитов
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
DE69214647T2 (de) Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: VONNEMANN, KLOIBER & KOLLEGEN, 80796 MUENCHEN

8339 Ceased/non-payment of the annual fee